Cargando…

Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies

Inherited neuropathies known as Charcot-Marie-Tooth (CMT) disease are genetically heterogeneous disorders affecting the peripheral nerves, causing significant and slowly progressive disability over the lifespan. The discovery of their diverse molecular genetic mechanisms over the past three decades...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stavrou, Marina, Sargiannidou, Irene, Georgiou, Elena, Kagiava, Alexia, Kleopa, Kleopas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199910/ https://www.ncbi.nlm.nih.gov/pubmed/34205075 http://dx.doi.org/10.3390/ijms22116048

Ejemplares similares

Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy
por: Schiza, Natasa, et al.
Publicado: (2019)

Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease
por: Olympiou, Margarita, et al.
Publicado: (2016)

NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice
por: Jennings, Matthew J, et al.
Publicado: (2022)

Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy
por: Kagiava, Alexia, et al.
Publicado: (2023)

AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy
por: Kagiava, Alexia, et al.
Publicado: (2021)

Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy
por: Sames, Lori, et al.
Publicado: (2014)

Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development
por: Juneja, Manisha, et al.
Publicado: (2019)

Dysregulation of Blood-Brain Barrier and Exacerbated Inflammatory Response in Cx47-Deficient Mice after Induction of EAE
por: Stavropoulos, Filippos, et al.
Publicado: (2021)

Altered Expression of Glial Gap Junction Proteins Cx43, Cx30, and Cx47 in the 5XFAD Model of Alzheimer’s Disease
por: Angeli, Stella, et al.
Publicado: (2020)

Charcot-Marie-Tooth: From Molecules to Therapy
por: Morena, Jonathan, et al.
Publicado: (2019)

AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy
por: Sahenk, Zarife, et al.
Publicado: (2014)

CMT1A current gene therapy approaches and promising biomarkers
por: Stavrou, Marina, et al.
Publicado: (2022)

Transient, Recurrent Central Nervous System Clinical Manifestations of X-Linked Charcot-Marie-Tooth Disease Presenting with Very Long Latency Periods between Episodes: Is Prolonged Sun Exposure a Provoking Factor?
por: Tziakouri, Andria, et al.
Publicado: (2020)

A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients
por: Wang, Wenjia, et al.
Publicado: (2017)

Diagnosis of Charcot-Marie-Tooth Disease
por: Banchs, Isabel, et al.
Publicado: (2009)

The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C
por: Skott, Humberto, et al.
Publicado: (2019)

Drosophila Models for Charcot–Marie–Tooth Neuropathy Related to Aminoacyl-tRNA Synthetases
por: Morant, Laura, et al.
Publicado: (2021)

Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives
por: Pisciotta, Chiara, et al.
Publicado: (2021)

Alterations of autophagy in the peripheral neuropathy Charcot-Marie-Tooth type 2B
por: Colecchia, David, et al.
Publicado: (2018)

SIRT2‐knockdown rescues GARS‐induced Charcot‐Marie‐Tooth neuropathy
por: Zhao, Yingying, et al.
Publicado: (2021)

Mitochondria dysfunction in Charcot Marie Tooth 2B Peripheral Sensory Neuropathy
por: Gu, Yingli, et al.
Publicado: (2022)

Aberrant Mitochondrial Dynamics and Exacerbated Response to Neuroinflammation in a Novel Mouse Model of CMT2A
por: Stavropoulos, Filippos, et al.
Publicado: (2021)

Charcot-Marie-Tooth Disease: Seventeen Causative Genes
por: Lee, Jung-Hwa, et al.
Publicado: (2006)

The Current State of Charcot–Marie–Tooth Disease Treatment
por: Okamoto, Yuji, et al.
Publicado: (2023)

Neural and Molecular Features on Charcot-Marie-Tooth Disease Plasticity and Therapy
por: Juárez, Paula, et al.
Publicado: (2012)

A Mutation in PMP2 Causes Dominant Demyelinating Charcot-Marie-Tooth Neuropathy
por: Hong, Young Bin, et al.
Publicado: (2016)

The allelic spectrum of Charcot–Marie–Tooth disease in over 17,000 individuals with neuropathy
por: DiVincenzo, Christina, et al.
Publicado: (2014)

Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy
por: Sainio, Markus T., et al.
Publicado: (2018)

Efficacy of exogenous pyruvate in Trembler(J) mouse model of Charcot‐Marie‐Tooth neuropathy
por: Sahenk, Zarife, et al.
Publicado: (2018)

PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies
por: van Paassen, Barbara W, et al.
Publicado: (2014)

Charcot–Marie–Tooth disease and intracellular traffic
por: Bucci, Cecilia, et al.
Publicado: (2012)

Noncompaction Cardiomyopathy with Charcot-Marie-Tooth Disease
por: Eltawansy, Sherif Ali, et al.
Publicado: (2015)

Anejaculation in a patient with Charcot–Marie–Tooth
por: Cannarella, Rossella, et al.
Publicado: (2018)

Audiological findings in the Charcot-Marie-Tooth Disease
por: Fukushima, Erika, et al.
Publicado: (2015)

Charcot-Marie-Tooth neuropathy score and ambulation index are both predictors of orthotic need for patients with CMT
por: Prada, Valeria, et al.
Publicado: (2021)

Recent Advances in Drosophila Models of Charcot-Marie-Tooth Disease
por: Kitani-Morii, Fukiko, et al.
Publicado: (2020)

Therapeutic Development in Charcot Marie Tooth Type 1 Disease
por: Miniou, Pierre, et al.
Publicado: (2021)

Daytime sleepiness and sleep quality in Charcot–Marie–Tooth disease
por: Bellofatto, Marta, et al.
Publicado: (2023)

Epitope-Tagged P(0)Glycoprotein Causes Charcot-Marie-Tooth–Like Neuropathy in Transgenic Mice
por: Previtali, Stefano C., et al.
Publicado: (2000)

A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice
por: Stavrou, Marina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dflqqfusfidebrc9gfmlmfphrr